Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1817493 | 1.00 | KDM4E (0.67) | KDM4EPOLBALDH1A1MAPTHTT | |
| SCHEMBL6926549 | 0.85 | HRH3 (0.55) | KDM4EPOLBHRH3FKBP1A | |
| SCHEMBL27506096 | 0.85 | KDM4E (0.62) | KDM4EPOLBALDH1A1MAPTHTT | |
| SCHEMBL1819248 | 0.84 | CYP1A2 (0.60) | CYP1A2CYP2C19 | |
| SCHEMBL2587055 | 0.84 | CYP1A2 (0.60) | CYP1A2CYP2C19 | |
| SCHEMBL1972076 | 0.84 | CYP1A2 (0.60) | CYP1A2CYP2C19 | |
| SCHEMBL2028510 | 0.83 | KDM4E (0.52) | KDM4EPOLBALDH1A1HRH3CYP1A2 | |
| SCHEMBL1820435 | 0.83 | KDM4E (0.52) | KDM4EPOLBALDH1A1HRH3CYP1A2 | |
| Hydrochloric Acid SCHEMBL20790624 | 0.83 | CYP1A2 (0.59) | ACECYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL992443 | 0.83 | CYP1A2 (0.59) | ACECYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2025-04-03 | — | — | US | disclosed |
| US-10174077-B2 | Method of inhibiting activity of cell surface fibroblast activation protein alpha | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2019-01-08 | — | — | US | disclosed |
| US-10155789-B2 | Substrates and inhibitors of prolyl oligopeptidase and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2018-12-18 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
| US-20170260231-A1 | Substrates and Inhibitors of Prolyl Oligopeptidase and Methods of Use Thereof | UNIV OKLAHOMA (US) | 2017-09-14 | — | — | US | disclosed |
| US-9688722-B2 | Substrates and inhibitors of prolyl oligopeptidase and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170066800-A1 | Substrates and Inhibitors of Antiplasmin Cleaving Enzyme and Fibroblast Activation Protein and Methods of Use | UNIV OKLAHOMA (US) | 2017-03-09 | — | — | US | disclosed |
| US-9527884-B2 | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150141660-A1 | Substrates and Inhibitors of Antiplasmin Cleaving Enzyme and Fibroblast Activation Protein and Methods of Use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-21 | — | — | US | disclosed |
| US-20150119330-A1 | SUBSTRATES AND INHIBITORS OF PROLYL OLIGOPEPTIDASE AND FIBROBLAST ACTIVATION PROTEIN AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2015-04-30 | — | — | US | disclosed |
| US-8933201-B2 | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2015-01-13 | — | — | US | disclosed |
| WO-2013166438-A1 | SUBSTRATES AND INHIBITORS OF PROLYL OLIGOPEPTIDASE AND FIBROBLAST ACTIVATION PROTEIN AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2013-11-07 | — | — | WO | disclosed |
| US-20110144037-A1 | Substrates and Inhibitors of Antiplasmin Cleaving Enzyme and Fibroblast Activation Protein and Methods of Use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2011-06-16 | — | — | US | disclosed |
| CN-101512338-A | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use thereof | MCKEE PATRICK A (US) | 2009-08-19 | — | — | CN | disclosed |
| EP-2038653-A2 | SUBSTRATES AND INHIBITORS OF ANTIPLASMIN CLEAVING ENZYME AND METHODS OF USE | McKee, Patrick A. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008119005-A1 | 3,4-DEHYDRO-PROLINE-CONTAINING INHIBITORS OF DIPEPTIDYLPEPTIDASE IV | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-02 | — | — | WO | disclosed |
| US-20080057491-A1 | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-03-06 | — | — | US | disclosed |
| WO-2008022015-A2 | RETRO-INVERSO INCRETIN ANALOGUES, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007146104-A2 | SUBSTRATES AND INHIBITORS OF ANTIPLASMIN CLEAVING ENZYME AND METHODS OF USE | MCKEE PATRICK A (US) | 2007-12-21 | — | — | WO | disclosed |
| US-6194426-B1 | CONTROLLING TUMOR NECROSIS FACTOR | RHONA-POULENC RORER S.A. (FR) | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | KDM4E 2409/4885POLB 3339/4885ALDH1A1 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.